Fig. 3.

GSK2193874 inhibits NMDA receptor function. A GSK2193874 inhibits NR2B phosphorylation in the hippocampus of rats exposed to soman. Soman group: rats were treated with HI-6 (125 mg/kg i.p.) before soman injection (160 μg/kg, s.c.); GSK2193874 (GSK) group: rats were additionally treated with the TRPV4 antagonist GSK2193874 (1 mg/kg, i.v.) immediately after HI-6 injection and before soman injection; Control group: rats received HI-6 and solvent instead of the antagonist and soman (mean ± SD, n = 6; ***P <0.001 vs control group, ^###P <0.001 vs soman group, one-way ANOVA and Dunnett’s multiple comparison test). B GSK2193874 inhibits I_NMDA in primary cultured rat hippocampal neurons. In the presence of 0.3 μmol/L and 3 μmol/L GSK2193874, I_NMDA decreases by 11.13 ± 2.67% and 19.11 ± 2.24%, respectively (n = 6; **P <0.01, ***P <0.001 vs NMDA 100 μmol/L group, paired t-test).